The Impact of Letermovir on Tacrolimus Pharmacokinetics and Clinical Outcomes Among Allogeneic Hematopoietic Cell Transplant Recipients (HOPA 2026) - Mar 28, 2026 - Abstract #TR225; Pres time: Mar 26, 2026; 01:00 PM - 02:00 PM; Location: Exhibit Hall I2; "Letermovir was routinely initiated on D+15, while tacrolimus was initiated on D-3 for traditional aGVHD prophylaxis and D+5 for post-transplant cyclophosphamide. This study demonstrated a significant tacrolimus-letermovir DDI resulting in lower weight-adjusted tacrolimus doses. However, the study suggests the DDI is not likely clinically significant, and empiric tacrolimus dose adjustments are not required with letermovir initiation."
Clinical • Clinical data • PK/PD data • Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation
|